Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma
Aim To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma. Methods In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinom...
Gespeichert in:
| Veröffentlicht in: | United European gastroenterology journal 2021-11, Vol.9 (9), p.1066-1073 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1073 |
|---|---|
| container_issue | 9 |
| container_start_page | 1066 |
| container_title | United European gastroenterology journal |
| container_volume | 9 |
| creator | Ven, Steffi E. M. Suzuki, Lucia Gotink, Annieke W. ten Kate, Fiebo J. C. Nieboer, Daan Weusten, Bas L. A. M. Brosens, Lodewijk A. A. Hillegersberg, Richard Alvarez Herrero, Lorenza Seldenrijk, Cees A. Alkhalaf, Alaa Moll, Freek C. P. Curvers, Wouter Lijnschoten, Ineke G. Tang, Thjon J. Valk, Hans Nagengast, Wouter B. Kats‐Ugurlu, Gursah Plukker, John T. M. Houben, Martin H. M. G. Laan, Jaap S. Pouw, Roos E. Bergman, Jacques J. G. H. M. Meijer, Sybren L. Berge Henegouwen, Mark I. Wijnhoven, Bas P. L. Jonge, Pieter J. F. Doukas, Michael Bruno, Marco J. Biermann, Katharina Koch, Arjun D. |
| description | Aim
To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma.
Methods
In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinoma. Primary endpoint was the presence of metastases, lymph node metastases, or distant metastases, in surgical resection specimens or during follow‐up. A prediction model to identify risk factors for metastases was developed and internally validated.
Results
248 patients were included. LVI was distributed as follows: no LVI (n = 196; 79.0%), 1 LVI focus (n = 16; 6.5%), 2–3 LVI foci (n = 21; 8.5%) and ≥4 LVI foci (n = 15; 6.0%). Seventy‐eight patients had metastases. The risk of metastases was increased for tumors with 2–3 LVI foci [subdistribution hazard ratio (SHR) 3.39, 95% confidence interval (CI) 2.10–5.47] and ≥4 LVI foci (SHR 3.81, 95% CI 2.37–6.10). The prediction model demonstrated a good discriminative ability (c‐statistic 0.81).
Conclusion
The risk of metastases is higher when more LVI foci are present. Quantification of LVI could be useful for a more precise risk estimation of metastases. This model needs to be externally validated before implementation into clinical practice. |
| doi_str_mv | 10.1002/ueg2.12151 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8598963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3090899342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4481-7debde11483329277ba885916d02bac51d8ad01bd27888f5c780f5fd314eb7703</originalsourceid><addsrcrecordid>eNp9kd9qHCEUh4fS0oQ0N32AIvQmDWzqvxmdm0IIaVpY6E1yLY6e2TWd0YmOG_ZR-rZ1s8nS9qIieNSPzyO_qnpP8AXBmH7OsKIXhJKavKqOKa7xouGEvz7UuDmqTlO6x2VIySnlb6sjxhvcYtEcV7-W23Fah41OJg86IudL6YJHD1n72fXO6Hm3NSEPFrlximEDKLr0E00RrDNPt6FHw86DfLCARph1KhNS0aGpCMDPCT26eY1S7sZsQtIDOrsl3ScEKUxrvYJyoC34YHQ0zodRv6ve9HpIcPq8nlR3X69vr74tlj9uvl9dLheGc0kWwkJngRAuGaMtFaLTUtYtaSymnTY1sVJbTDpLhZSyr42QuK97ywiHTgjMTqove-9UWgNrSq9RD2qKbtRxq4J26u8b79ZqFTaqvCLbhhXB2bMghocMaVajSwaGQXsIOSlai5aJpmVtQT_-g96HHH35nmIlENm2jNNCne8pE0NKEfpDMwSrXehqF7p6Cr3AH_5s_4C-RFwAsgce3QDb_6jU3fUN3Ut_A__Iusc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090899342</pqid></control><display><type>article</type><title>Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Ven, Steffi E. M. ; Suzuki, Lucia ; Gotink, Annieke W. ; ten Kate, Fiebo J. C. ; Nieboer, Daan ; Weusten, Bas L. A. M. ; Brosens, Lodewijk A. A. ; Hillegersberg, Richard ; Alvarez Herrero, Lorenza ; Seldenrijk, Cees A. ; Alkhalaf, Alaa ; Moll, Freek C. P. ; Curvers, Wouter ; Lijnschoten, Ineke G. ; Tang, Thjon J. ; Valk, Hans ; Nagengast, Wouter B. ; Kats‐Ugurlu, Gursah ; Plukker, John T. M. ; Houben, Martin H. M. G. ; Laan, Jaap S. ; Pouw, Roos E. ; Bergman, Jacques J. G. H. M. ; Meijer, Sybren L. ; Berge Henegouwen, Mark I. ; Wijnhoven, Bas P. L. ; Jonge, Pieter J. F. ; Doukas, Michael ; Bruno, Marco J. ; Biermann, Katharina ; Koch, Arjun D.</creator><creatorcontrib>Ven, Steffi E. M. ; Suzuki, Lucia ; Gotink, Annieke W. ; ten Kate, Fiebo J. C. ; Nieboer, Daan ; Weusten, Bas L. A. M. ; Brosens, Lodewijk A. A. ; Hillegersberg, Richard ; Alvarez Herrero, Lorenza ; Seldenrijk, Cees A. ; Alkhalaf, Alaa ; Moll, Freek C. P. ; Curvers, Wouter ; Lijnschoten, Ineke G. ; Tang, Thjon J. ; Valk, Hans ; Nagengast, Wouter B. ; Kats‐Ugurlu, Gursah ; Plukker, John T. M. ; Houben, Martin H. M. G. ; Laan, Jaap S. ; Pouw, Roos E. ; Bergman, Jacques J. G. H. M. ; Meijer, Sybren L. ; Berge Henegouwen, Mark I. ; Wijnhoven, Bas P. L. ; Jonge, Pieter J. F. ; Doukas, Michael ; Bruno, Marco J. ; Biermann, Katharina ; Koch, Arjun D.</creatorcontrib><description>Aim
To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma.
Methods
In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinoma. Primary endpoint was the presence of metastases, lymph node metastases, or distant metastases, in surgical resection specimens or during follow‐up. A prediction model to identify risk factors for metastases was developed and internally validated.
Results
248 patients were included. LVI was distributed as follows: no LVI (n = 196; 79.0%), 1 LVI focus (n = 16; 6.5%), 2–3 LVI foci (n = 21; 8.5%) and ≥4 LVI foci (n = 15; 6.0%). Seventy‐eight patients had metastases. The risk of metastases was increased for tumors with 2–3 LVI foci [subdistribution hazard ratio (SHR) 3.39, 95% confidence interval (CI) 2.10–5.47] and ≥4 LVI foci (SHR 3.81, 95% CI 2.37–6.10). The prediction model demonstrated a good discriminative ability (c‐statistic 0.81).
Conclusion
The risk of metastases is higher when more LVI foci are present. Quantification of LVI could be useful for a more precise risk estimation of metastases. This model needs to be externally validated before implementation into clinical practice.</description><identifier>ISSN: 2050-6406</identifier><identifier>EISSN: 2050-6414</identifier><identifier>DOI: 10.1002/ueg2.12151</identifier><identifier>PMID: 34609076</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adenocarcinoma - pathology ; Aged ; Cancer ; Dissection ; endoscopic mucosal resection ; Endoscopy ; Esophageal cancer ; Esophageal Neoplasms - pathology ; esophagectomy lLymphovascular invasion ; Esophagus ; Female ; Humans ; LVI ; lymph node metastases ; Lymph Nodes - pathology ; Lymphatic Metastasis ; Lymphatic system ; Male ; Metastasis ; Middle Aged ; Neoplasm Invasiveness ; Original ; Patients ; prediction ; quantification ; Regression Analysis ; Retrospective Studies ; risk assessment ; Risk Factors ; submucosal esophageal adenocarcinoma ; Surgery ; T1b adenocarcinoma ; Tumors</subject><ispartof>United European gastroenterology journal, 2021-11, Vol.9 (9), p.1066-1073</ispartof><rights>2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4481-7debde11483329277ba885916d02bac51d8ad01bd27888f5c780f5fd314eb7703</citedby><cites>FETCH-LOGICAL-c4481-7debde11483329277ba885916d02bac51d8ad01bd27888f5c780f5fd314eb7703</cites><orcidid>0000-0002-4707-1186 ; 0000-0003-0509-3472 ; 0000-0001-9793-0957</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598963/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598963/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34609076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ven, Steffi E. M.</creatorcontrib><creatorcontrib>Suzuki, Lucia</creatorcontrib><creatorcontrib>Gotink, Annieke W.</creatorcontrib><creatorcontrib>ten Kate, Fiebo J. C.</creatorcontrib><creatorcontrib>Nieboer, Daan</creatorcontrib><creatorcontrib>Weusten, Bas L. A. M.</creatorcontrib><creatorcontrib>Brosens, Lodewijk A. A.</creatorcontrib><creatorcontrib>Hillegersberg, Richard</creatorcontrib><creatorcontrib>Alvarez Herrero, Lorenza</creatorcontrib><creatorcontrib>Seldenrijk, Cees A.</creatorcontrib><creatorcontrib>Alkhalaf, Alaa</creatorcontrib><creatorcontrib>Moll, Freek C. P.</creatorcontrib><creatorcontrib>Curvers, Wouter</creatorcontrib><creatorcontrib>Lijnschoten, Ineke G.</creatorcontrib><creatorcontrib>Tang, Thjon J.</creatorcontrib><creatorcontrib>Valk, Hans</creatorcontrib><creatorcontrib>Nagengast, Wouter B.</creatorcontrib><creatorcontrib>Kats‐Ugurlu, Gursah</creatorcontrib><creatorcontrib>Plukker, John T. M.</creatorcontrib><creatorcontrib>Houben, Martin H. M. G.</creatorcontrib><creatorcontrib>Laan, Jaap S.</creatorcontrib><creatorcontrib>Pouw, Roos E.</creatorcontrib><creatorcontrib>Bergman, Jacques J. G. H. M.</creatorcontrib><creatorcontrib>Meijer, Sybren L.</creatorcontrib><creatorcontrib>Berge Henegouwen, Mark I.</creatorcontrib><creatorcontrib>Wijnhoven, Bas P. L.</creatorcontrib><creatorcontrib>Jonge, Pieter J. F.</creatorcontrib><creatorcontrib>Doukas, Michael</creatorcontrib><creatorcontrib>Bruno, Marco J.</creatorcontrib><creatorcontrib>Biermann, Katharina</creatorcontrib><creatorcontrib>Koch, Arjun D.</creatorcontrib><title>Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma</title><title>United European gastroenterology journal</title><addtitle>United European Gastroenterol J</addtitle><description>Aim
To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma.
Methods
In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinoma. Primary endpoint was the presence of metastases, lymph node metastases, or distant metastases, in surgical resection specimens or during follow‐up. A prediction model to identify risk factors for metastases was developed and internally validated.
Results
248 patients were included. LVI was distributed as follows: no LVI (n = 196; 79.0%), 1 LVI focus (n = 16; 6.5%), 2–3 LVI foci (n = 21; 8.5%) and ≥4 LVI foci (n = 15; 6.0%). Seventy‐eight patients had metastases. The risk of metastases was increased for tumors with 2–3 LVI foci [subdistribution hazard ratio (SHR) 3.39, 95% confidence interval (CI) 2.10–5.47] and ≥4 LVI foci (SHR 3.81, 95% CI 2.37–6.10). The prediction model demonstrated a good discriminative ability (c‐statistic 0.81).
Conclusion
The risk of metastases is higher when more LVI foci are present. Quantification of LVI could be useful for a more precise risk estimation of metastases. This model needs to be externally validated before implementation into clinical practice.</description><subject>Adenocarcinoma - pathology</subject><subject>Aged</subject><subject>Cancer</subject><subject>Dissection</subject><subject>endoscopic mucosal resection</subject><subject>Endoscopy</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - pathology</subject><subject>esophagectomy lLymphovascular invasion</subject><subject>Esophagus</subject><subject>Female</subject><subject>Humans</subject><subject>LVI</subject><subject>lymph node metastases</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Original</subject><subject>Patients</subject><subject>prediction</subject><subject>quantification</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><subject>risk assessment</subject><subject>Risk Factors</subject><subject>submucosal esophageal adenocarcinoma</subject><subject>Surgery</subject><subject>T1b adenocarcinoma</subject><subject>Tumors</subject><issn>2050-6406</issn><issn>2050-6414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kd9qHCEUh4fS0oQ0N32AIvQmDWzqvxmdm0IIaVpY6E1yLY6e2TWd0YmOG_ZR-rZ1s8nS9qIieNSPzyO_qnpP8AXBmH7OsKIXhJKavKqOKa7xouGEvz7UuDmqTlO6x2VIySnlb6sjxhvcYtEcV7-W23Fah41OJg86IudL6YJHD1n72fXO6Hm3NSEPFrlximEDKLr0E00RrDNPt6FHw86DfLCARph1KhNS0aGpCMDPCT26eY1S7sZsQtIDOrsl3ScEKUxrvYJyoC34YHQ0zodRv6ve9HpIcPq8nlR3X69vr74tlj9uvl9dLheGc0kWwkJngRAuGaMtFaLTUtYtaSymnTY1sVJbTDpLhZSyr42QuK97ywiHTgjMTqove-9UWgNrSq9RD2qKbtRxq4J26u8b79ZqFTaqvCLbhhXB2bMghocMaVajSwaGQXsIOSlai5aJpmVtQT_-g96HHH35nmIlENm2jNNCne8pE0NKEfpDMwSrXehqF7p6Cr3AH_5s_4C-RFwAsgce3QDb_6jU3fUN3Ut_A__Iusc</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Ven, Steffi E. M.</creator><creator>Suzuki, Lucia</creator><creator>Gotink, Annieke W.</creator><creator>ten Kate, Fiebo J. C.</creator><creator>Nieboer, Daan</creator><creator>Weusten, Bas L. A. M.</creator><creator>Brosens, Lodewijk A. A.</creator><creator>Hillegersberg, Richard</creator><creator>Alvarez Herrero, Lorenza</creator><creator>Seldenrijk, Cees A.</creator><creator>Alkhalaf, Alaa</creator><creator>Moll, Freek C. P.</creator><creator>Curvers, Wouter</creator><creator>Lijnschoten, Ineke G.</creator><creator>Tang, Thjon J.</creator><creator>Valk, Hans</creator><creator>Nagengast, Wouter B.</creator><creator>Kats‐Ugurlu, Gursah</creator><creator>Plukker, John T. M.</creator><creator>Houben, Martin H. M. G.</creator><creator>Laan, Jaap S.</creator><creator>Pouw, Roos E.</creator><creator>Bergman, Jacques J. G. H. M.</creator><creator>Meijer, Sybren L.</creator><creator>Berge Henegouwen, Mark I.</creator><creator>Wijnhoven, Bas P. L.</creator><creator>Jonge, Pieter J. F.</creator><creator>Doukas, Michael</creator><creator>Bruno, Marco J.</creator><creator>Biermann, Katharina</creator><creator>Koch, Arjun D.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4707-1186</orcidid><orcidid>https://orcid.org/0000-0003-0509-3472</orcidid><orcidid>https://orcid.org/0000-0001-9793-0957</orcidid></search><sort><creationdate>202111</creationdate><title>Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma</title><author>Ven, Steffi E. M. ; Suzuki, Lucia ; Gotink, Annieke W. ; ten Kate, Fiebo J. C. ; Nieboer, Daan ; Weusten, Bas L. A. M. ; Brosens, Lodewijk A. A. ; Hillegersberg, Richard ; Alvarez Herrero, Lorenza ; Seldenrijk, Cees A. ; Alkhalaf, Alaa ; Moll, Freek C. P. ; Curvers, Wouter ; Lijnschoten, Ineke G. ; Tang, Thjon J. ; Valk, Hans ; Nagengast, Wouter B. ; Kats‐Ugurlu, Gursah ; Plukker, John T. M. ; Houben, Martin H. M. G. ; Laan, Jaap S. ; Pouw, Roos E. ; Bergman, Jacques J. G. H. M. ; Meijer, Sybren L. ; Berge Henegouwen, Mark I. ; Wijnhoven, Bas P. L. ; Jonge, Pieter J. F. ; Doukas, Michael ; Bruno, Marco J. ; Biermann, Katharina ; Koch, Arjun D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4481-7debde11483329277ba885916d02bac51d8ad01bd27888f5c780f5fd314eb7703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Aged</topic><topic>Cancer</topic><topic>Dissection</topic><topic>endoscopic mucosal resection</topic><topic>Endoscopy</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - pathology</topic><topic>esophagectomy lLymphovascular invasion</topic><topic>Esophagus</topic><topic>Female</topic><topic>Humans</topic><topic>LVI</topic><topic>lymph node metastases</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Original</topic><topic>Patients</topic><topic>prediction</topic><topic>quantification</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><topic>risk assessment</topic><topic>Risk Factors</topic><topic>submucosal esophageal adenocarcinoma</topic><topic>Surgery</topic><topic>T1b adenocarcinoma</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ven, Steffi E. M.</creatorcontrib><creatorcontrib>Suzuki, Lucia</creatorcontrib><creatorcontrib>Gotink, Annieke W.</creatorcontrib><creatorcontrib>ten Kate, Fiebo J. C.</creatorcontrib><creatorcontrib>Nieboer, Daan</creatorcontrib><creatorcontrib>Weusten, Bas L. A. M.</creatorcontrib><creatorcontrib>Brosens, Lodewijk A. A.</creatorcontrib><creatorcontrib>Hillegersberg, Richard</creatorcontrib><creatorcontrib>Alvarez Herrero, Lorenza</creatorcontrib><creatorcontrib>Seldenrijk, Cees A.</creatorcontrib><creatorcontrib>Alkhalaf, Alaa</creatorcontrib><creatorcontrib>Moll, Freek C. P.</creatorcontrib><creatorcontrib>Curvers, Wouter</creatorcontrib><creatorcontrib>Lijnschoten, Ineke G.</creatorcontrib><creatorcontrib>Tang, Thjon J.</creatorcontrib><creatorcontrib>Valk, Hans</creatorcontrib><creatorcontrib>Nagengast, Wouter B.</creatorcontrib><creatorcontrib>Kats‐Ugurlu, Gursah</creatorcontrib><creatorcontrib>Plukker, John T. M.</creatorcontrib><creatorcontrib>Houben, Martin H. M. G.</creatorcontrib><creatorcontrib>Laan, Jaap S.</creatorcontrib><creatorcontrib>Pouw, Roos E.</creatorcontrib><creatorcontrib>Bergman, Jacques J. G. H. M.</creatorcontrib><creatorcontrib>Meijer, Sybren L.</creatorcontrib><creatorcontrib>Berge Henegouwen, Mark I.</creatorcontrib><creatorcontrib>Wijnhoven, Bas P. L.</creatorcontrib><creatorcontrib>Jonge, Pieter J. F.</creatorcontrib><creatorcontrib>Doukas, Michael</creatorcontrib><creatorcontrib>Bruno, Marco J.</creatorcontrib><creatorcontrib>Biermann, Katharina</creatorcontrib><creatorcontrib>Koch, Arjun D.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>United European gastroenterology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ven, Steffi E. M.</au><au>Suzuki, Lucia</au><au>Gotink, Annieke W.</au><au>ten Kate, Fiebo J. C.</au><au>Nieboer, Daan</au><au>Weusten, Bas L. A. M.</au><au>Brosens, Lodewijk A. A.</au><au>Hillegersberg, Richard</au><au>Alvarez Herrero, Lorenza</au><au>Seldenrijk, Cees A.</au><au>Alkhalaf, Alaa</au><au>Moll, Freek C. P.</au><au>Curvers, Wouter</au><au>Lijnschoten, Ineke G.</au><au>Tang, Thjon J.</au><au>Valk, Hans</au><au>Nagengast, Wouter B.</au><au>Kats‐Ugurlu, Gursah</au><au>Plukker, John T. M.</au><au>Houben, Martin H. M. G.</au><au>Laan, Jaap S.</au><au>Pouw, Roos E.</au><au>Bergman, Jacques J. G. H. M.</au><au>Meijer, Sybren L.</au><au>Berge Henegouwen, Mark I.</au><au>Wijnhoven, Bas P. L.</au><au>Jonge, Pieter J. F.</au><au>Doukas, Michael</au><au>Bruno, Marco J.</au><au>Biermann, Katharina</au><au>Koch, Arjun D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma</atitle><jtitle>United European gastroenterology journal</jtitle><addtitle>United European Gastroenterol J</addtitle><date>2021-11</date><risdate>2021</risdate><volume>9</volume><issue>9</issue><spage>1066</spage><epage>1073</epage><pages>1066-1073</pages><issn>2050-6406</issn><eissn>2050-6414</eissn><abstract>Aim
To quantify lymphovascular invasion (LVI) and to assess the prognostic value in patients with pT1b esophageal adenocarcinoma.
Methods
In this nationwide, retrospective cohort study, patients were included if they were treated with surgery or endoscopic resection for pT1b esophageal adenocarcinoma. Primary endpoint was the presence of metastases, lymph node metastases, or distant metastases, in surgical resection specimens or during follow‐up. A prediction model to identify risk factors for metastases was developed and internally validated.
Results
248 patients were included. LVI was distributed as follows: no LVI (n = 196; 79.0%), 1 LVI focus (n = 16; 6.5%), 2–3 LVI foci (n = 21; 8.5%) and ≥4 LVI foci (n = 15; 6.0%). Seventy‐eight patients had metastases. The risk of metastases was increased for tumors with 2–3 LVI foci [subdistribution hazard ratio (SHR) 3.39, 95% confidence interval (CI) 2.10–5.47] and ≥4 LVI foci (SHR 3.81, 95% CI 2.37–6.10). The prediction model demonstrated a good discriminative ability (c‐statistic 0.81).
Conclusion
The risk of metastases is higher when more LVI foci are present. Quantification of LVI could be useful for a more precise risk estimation of metastases. This model needs to be externally validated before implementation into clinical practice.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>34609076</pmid><doi>10.1002/ueg2.12151</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-4707-1186</orcidid><orcidid>https://orcid.org/0000-0003-0509-3472</orcidid><orcidid>https://orcid.org/0000-0001-9793-0957</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2050-6406 |
| ispartof | United European gastroenterology journal, 2021-11, Vol.9 (9), p.1066-1073 |
| issn | 2050-6406 2050-6414 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8598963 |
| source | MEDLINE; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Adenocarcinoma - pathology Aged Cancer Dissection endoscopic mucosal resection Endoscopy Esophageal cancer Esophageal Neoplasms - pathology esophagectomy lLymphovascular invasion Esophagus Female Humans LVI lymph node metastases Lymph Nodes - pathology Lymphatic Metastasis Lymphatic system Male Metastasis Middle Aged Neoplasm Invasiveness Original Patients prediction quantification Regression Analysis Retrospective Studies risk assessment Risk Factors submucosal esophageal adenocarcinoma Surgery T1b adenocarcinoma Tumors |
| title | Lymphovascular invasion quantification could improve risk prediction of lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T02%3A04%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lymphovascular%20invasion%20quantification%20could%20improve%20risk%20prediction%20of%20lymph%20node%20metastases%20in%20patients%20with%20submucosal%20(T1b)%20esophageal%20adenocarcinoma&rft.jtitle=United%20European%20gastroenterology%20journal&rft.au=Ven,%20Steffi%20E.%20M.&rft.date=2021-11&rft.volume=9&rft.issue=9&rft.spage=1066&rft.epage=1073&rft.pages=1066-1073&rft.issn=2050-6406&rft.eissn=2050-6414&rft_id=info:doi/10.1002/ueg2.12151&rft_dat=%3Cproquest_pubme%3E3090899342%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3090899342&rft_id=info:pmid/34609076&rfr_iscdi=true |